Thyrocare Technologies Limited — PPTs, 23-07-2025: Investor Presentation

**1. Financial Highlights:**

Consolidated revenue grew 23% YoY to 193 Cr, primarily from 25% pathology growth. Normalized EBITDA increased 42% YoY to 63.35 Cr (33% margin). Profit after tax jumped 62% YoY to 38.06 Cr. Key operational metrics, including active franchisees, patients, and tests, also showed strong double-digit growth.

**2. Strategic Initiatives & Growth Drivers:**

The company expanded its PAN-India network with new labs in Bhagalpur, Kashmir, and Roorkee. Future strategy involves deeper market penetration, strengthening franchise/partner networks (e.g., insurance/ECG at home, PPP), and growing its Tanzanian presence.

**3. Business Developments:**

Relationship-building initiatives included a Doctor Advisory Board meeting and channel partner events. Recent acquisitions also contributed to inorganic revenue, complementing strong organic growth.

**4. Market Position & Competitive Advantage:**

With 40 labs nationwide, the company is India's first diagnostic chain to achieve 100% NABL accreditation across all facilities (Q4 FY25), emphasizing its commitment to high quality.

**5. Investor Implications:**

Strong organic growth, strategic expansion (organic and inorganic), and improved operating leverage point to positive growth potential. Continued network growth and partnerships are expected to drive sustained market penetration and revenue expansion.